Advertisement

Pharmaceutical Chemistry Journal

, Volume 53, Issue 5, pp 423–428 | Cite as

Synthesis, Antiproliferative Activity, and Effect on Carcinoma A549 Cell Microtubules of New Tubuloclustin Analogs

  • N. A. Zefirov
  • Yu. A. Evteeva
  • A. R. Fatkulin
  • S. Schulz
  • S. A. Kuznetsov
  • O. N. ZefirovaEmail author
Article
  • 14 Downloads

Combretastatin analogs of the antitumor agent tubuloclustin {N-[7-(adamant-2-yloxy)-7-oxoheptanoyl]-Ndeacetylcolchicine} were prepared via esterification of combretastatin by monoesters of pimelic or adipic acid with adamantan-2-ol or (adamantan-1-yl)methanol. These conjugates were stable and cytotoxic to human lung carcinoma A549 cells (EC50 ≈ 50 – 70 nM) and caused depolymerization of microtubules and slight clustering of tubulin. Tubuloclustin analogs with shortened linkers were prepared via amidation by N-deacetylcolchicine of monoesters of adipic or succinic acids with adamantan-1-ol or (adamantan-1-yl)methanol. The conjugate N-[6-(adamantyl)-6-oxohexanoyl]-N-deacetylcolchicine was more active (EC50 ≈ 4 nM) than tubuloclustin and promoted strong tubulin clusterization. All compounds induced apoptosis of A549 cells. Tests in vivo of N-[6-(adamantyl)-6-oxoheaxnoyl]-N-deacetylcolchicine on carcinoma A549 experimental models were concluded to be promising.

Keywords

carcinoma A549 tubuloclustin colchicine combretastatin adamantane 

Notes

Acknowledgments

The work was financially supported by RFBR Grant 18–33–01121 mol a. We thank German Academic Exchange Service DAAD for supporting an academic exchange under terms of a collaboration agreement between Moscow and Rostock Universities.

References

  1. 1.
    B. Kumar, R. Kumar, I. Skvortsova, and V. Kumar, Curr. Cancer Drug Targets, 17(4), 357 – 375 (2017).CrossRefGoogle Scholar
  2. 2.
    R. A. Stanton, K. M. Gernert, J. H. Nettles, and R. Aneja, Med. Res. Rev., 31(3), 443 – 481 (2011).CrossRefGoogle Scholar
  3. 3.
    S. Wu, J. Fisher, J. Naci, et al., Chem. Res. Toxicol., 26(12), 1840 – 1861 (2013).CrossRefGoogle Scholar
  4. 4.
    N. A. Zefirov and O. N. Zefirova, Zh. Org. Khim., 51(9), 1231 – 1240 (2015).Google Scholar
  5. 5.
    K. Nepali, S. Sharma, M. Sharma, et al., Eur. J. Med. Chem., 77, 422 – 487 (2014).CrossRefGoogle Scholar
  6. 6.
    E. C. Breen and J. J. Walsh, Curr. Med. Chem., 17, 609 – 639 (2010).CrossRefGoogle Scholar
  7. 7.
    C. Vilanova, S. Daaz-Oltra, J. Murga, et al., J. Med. Chem., 57(24), 10391 – 10403 (2014).CrossRefGoogle Scholar
  8. 8.
    S. K. Kim, S. M. Cho, H. Kim, et al., Exp. Mol. Med., 45, E19 (2013).CrossRefGoogle Scholar
  9. 9.
    P. Thomopoulou, J. Sachs, N. Teusch, et al., ACS Med. Chem. Lett., 7(2), 188 – 191 (2015).CrossRefGoogle Scholar
  10. 10.
    O. N. Zefirova, H. Lemcke, M. Lantow, et al., ChemBioChem, 14(12), 1444 – 1449 (2013).CrossRefGoogle Scholar
  11. 11.
    O. N. Zefirova, E. V. Nurieva, D. V. Shishov, et al., Bioorg. Med. Chem., 19(18), 5529 – 5538 (2011).CrossRefGoogle Scholar
  12. 12.
    O. N. Zefirova, E. V. Nurieva, Ya. S. Glazkova, et al., Khim.-farm. Zh., 48, No. 6, 19 – 24 (2014); Pharm. Chem. J., 48(6), 373 – 378 (2014).Google Scholar
  13. 13.
    N. A. Zefirov, M. Hoppe, I. V. Kuznetsova, et al., Mendeleev Commun., 28(3), 225 – 344 (2018).CrossRefGoogle Scholar
  14. 14.
    O. N. Zefirova, Ya. S. Glazkova, E. V. Nurieva, et al., Izv. Akad. Nauk, Ser. Khim., 5, 1126 – 1129 (2014).Google Scholar
  15. 15.
    O. N. Zefirova, E. V. Nurieva, B. Wobith, et al., Mol. Diversity, 21(3), 547 – 564 (2017).CrossRefGoogle Scholar
  16. 16.
    E. V. Nurieva, N. A. Zefirov, A. V. Mamaeva, et al., Izv. Akad. Nauk, Ser. Khim., 4, 688 – 693 (2018).Google Scholar
  17. 17.
    B. Coggiola, F. Pagliai, G. Allegrone, et al., Bioorg. Med. Chem. Lett., 15(15), 3551 – 3554 (2005).CrossRefGoogle Scholar
  18. 18.
    L. Lebeau, P. Ducray, and C. Mioskowski, Synth. Commun., 27(2), 293 – 296 (1997).CrossRefGoogle Scholar
  19. 19.
    J. D. Bagnato, A. L. Eilers, R. A. Horton, and C. B. Grissom, J. Org. Chem., 69(26), 8987 (2004).CrossRefGoogle Scholar
  20. 20.
    T. Mosmann, J. Immunol. Methods, 65(1 – 2), 55 – 63 (1983).CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • N. A. Zefirov
    • 1
    • 2
  • Yu. A. Evteeva
    • 1
  • A. R. Fatkulin
    • 1
  • S. Schulz
    • 3
  • S. A. Kuznetsov
    • 3
  • O. N. Zefirova
    • 1
    • 2
    Email author
  1. 1.M. V. Lomonosov Moscow State UniversityMoscowRussia
  2. 2.Institute of Physiologically Active CompoundsRussian Academy of SciencesChernogolovkaRussia
  3. 3.Institute of Biological SciencesUniversity of RostockRostockGermany

Personalised recommendations